OncoCyte Announces Andrea James as New CFO and Principal Officer
Company Announcements

OncoCyte Announces Andrea James as New CFO and Principal Officer

OncoCyte (OCX) just unveiled an announcement.

Oncocyte Corporation has appointed Andrea James as their new Chief Financial Officer and Principal Financial Officer, effective June 17, 2024. With a rich background in investor relations and corporate strategy, including senior roles at Axon Enterprise and strategic consultancy for Tesla, Inc., Ms. James brings a wealth of experience to the role. Her compensation includes a $325,000 base salary, with a potential annual bonus of 50%, along with comprehensive severance and equity terms. James has no familial ties to the company’s executives and her appointment is independent of any other agreements.

For detailed information about OCX stock, go to TipRanks’ Stock Analysis page.

Related Articles
Brian AndersonOCX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
TheFlyOncoCyte files to sell 3.46M shares of common stock for holders
TipRanks Auto-Generated NewsdeskOncoCyte Shareholders Approve Incentive Plan and Meeting Adjournment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App